Stock research
BMEA Biomea Fusion, Inc.
Healthcare • Biotechnology
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from...…
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
5Y change
-90.11%
Range high
$41.80
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in BMEA?
Price
Showing 5Y history. Source: FMP historical price full.
- Prev Close
- $1.23
- Day High
- $1.27
- Day Low
- $1.22
- 52w High
- $2.99
- 52w Low
- $0.87
- Volume
- 396,382
- Avg Volume
- Beta
- -0.329
* TTM/most recent where available
Company
- Ticker
- BMEA
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Michael J. Hitchcock
- Employees
- 41
- Website
- biomeafusion.com
Key Metrics
- Market Cap
- 91.1M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).